Basic Information
VIS ID
TVIS30014212
Fusion event
HIV-COLGALT1 integration
Validated
Yes
Detection method
invPCR
Data source
download(RID)
Sample type
PBMC
Disease
HIV-infected disease (HID)
Quality evaluation
Normal
Reported year
2007
PubMed ID
17262715
Virus Sequence
Virus name
HIV
Reference genome
Not given
Host Sequence
Chromosome
chr19
Cytoband
p13.11
Reference genome
GRCh37/hg19
Start
17669192/17558383 (Hg38)
End
17669192/17558383 (Hg38)
Orient
-
Location type
Intronic
Fragile sites / regions
FRA19B
Target gene
COLGALT1
miRNAs that regulate target gene
hsa-mir-155-5p ; hsa-mir-124-3p ; hsa-mir-98-5p ; hsa-mir-744-5p ; hsa-mir-532-3p ; hsa-mir-147a ; hsa-mir-6867-5p ; hsa-mir-644a ; hsa-mir-3911 ; hsa-mir-4769-5p ; hsa-mir-4654 ; hsa-mir-6778-5p ; hsa-mir-4648 ; hsa-mir-1233-5p ; hsa-mir-3650 ; hsa-mir-4786-3p ; hsa-mir-6515-3p ; hsa-mir-3934-5p ; hsa-mir-764 ; hsa-mir-125a-3p ; hsa-mir-1227-5p ; hsa-mir-128-1-5p ; hsa-mir-128-2-5p ; hsa-mir-3151-5p ; hsa-mir-328-5p ; hsa-mir-4489 ; hsa-mir-4685-5p ; hsa-mir-4733-3p ; hsa-mir-492 ; hsa-mir-664b-5p ; hsa-mir-6762-5p ; hsa-mir-6798-5p ; hsa-mir-6837-5p ; hsa-mir-6845-5p ; hsa-mir-6846-5p ; hsa-mir-6848-5p ; hsa-mir-6853-5p ; hsa-mir-6885-5p ; hsa-mir-6887-3p ; hsa-mir-7113-5p ; hsa-mir-1288-5p ; hsa-mir-3190-5p ; hsa-mir-3614-5p ; hsa-mir-3926 ; hsa-mir-4433a-3p ; hsa-mir-4459 ; hsa-mir-4768-3p ; hsa-mir-4786-5p ; hsa-mir-548s ; hsa-mir-6849-3p ; hsa-mir-7112-5p
Nearest miRNA
hsa-mir-10395/Upstream/2108775; hsa-let-7e/Downstream/723694;
Nearest TSS
ENST00000633603/Upstream/1822; ENST00000601354/Downstream/7650;
Nearest CpG islands
None/Target, chr19-CpG: 112/Upstream/2214, chr19-CpG: 29/Downstream/18820
Upstream sequence
aggctggtctcaaactcctgacctcaggtgatacacccgcctcggcctctcaaagtgctgggatgacaggcgtgagccaccgtgcctggccTGATCTATA
Downstream sequence
CATTACAAAAATTgccgtgtgcggtggctcattcctgtcatcccagcactttgggaggctgaggcaggtggatcacctgaggtcaggagttcgagagcag
Reference
Ikeda, T., et al. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis,2007, 195(5): 716-725.
Curate